Cell & Gene Therapy Applications
Leukopak vs PBMC vs Whole Blood: What’s the Difference and Which One Do You Need?
Leukopak vs PBMC vs Whole Blood: What’s the Difference and Which One Do You Need? Cell therapy, immunology, and translational research programs all rely on high quality human blood derived materials. But one of the most common sourcing questions researchers face is: Should I use whole blood, PBMCs, or a leukopak? The answer depends on…
For More InformationT Cell Activation in Cell Therapy: Why T Cell Activation Fails Without the Right Starting Material
Introduction T cell activation is a foundational step in cell and gene therapy workflows, particularly in CAR T and other adoptive cell therapies. While much attention is placed on genetic engineering and manufacturing scale, activation is where functional outcomes begin to take shape. When done correctly, it enables strong expansion, optimal phenotypes, and durable responses.…
For More InformationWhy CGT Global Is Positioned to Support the Next Wave of Cell and Gene Therapies
Cell and gene therapy companies rely on several critical pieces of infrastructure to move therapies from development to clinical trials and ultimately to patient treatment. These include reliable sources of GMP compatible starting material, clinical trial support for complex cell therapy workflows, and hospitals capable of administering advanced therapies. Without these components in place, even…
For More InformationB Cell CAR T in Autoimmune Disease Breaks for Predictable Operational Reasons
B Cell CAR T in Autoimmune Disease Breaks for Predictable Operational Reasons B cell directed CAR T programs in autoimmune disease rarely fail because of the cell. They stall because operational assumptions borrowed from oncology do not hold once real patients and real timelines enter the picture. Teams often discover this late, usually after their…
For More InformationEverything CGT Global Offers: Starting Materials, Isolated Cells, and Clinical Grade Supply
1. Leukopaks (RUO, Mobilized, Clinical, and GMP Aligned) Leukopaks remain one of the most common upstream inputs for immune cell workflows. We support formats that match how cell therapy teams actually operate. RUO leukopaks Fresh and cryopreserved options for discovery, preclinical, and process development. Mobilized leukopaks Mobilized options for programs requiring higher progenitor content or…
For More InformationGMP Leukopak Partner Guide for Clinical Development
Plus a Fresh vs Cryopreserved Decision Guide for Allogeneic Programs If you are building a cell therapy program, your starting material is not a minor detail. It is one of the biggest drivers of downstream consistency, cost, and timeline risk. That is why the GMP leukopak has become a cornerstone input for teams moving from…
For More InformationAdvancing CAR NK Therapy: Why Leukopak Quality and Donor Characterization Matter
CAR NK therapy is gaining traction as a next wave cell therapy platform. Compared to CAR T, CAR NK programs offer the potential for allogeneic manufacturing, improved safety profiles, and scalable off the shelf products. But CAR NK workflows are less forgiving when it comes to starting material. NK cells are more sensitive to collection…
For More InformationFresh vs Cryopreserved Leukopaks for T Cell Expansion and CAR T Manufacturing
Why the fresh vs cryo decision matters Most CAR T processes are built around predictable inputs. When those inputs shift, it becomes harder to hit target yields, expansion timing, and manufacturing release criteria. Fresh and cryopreserved leukopaks differ in: logistics and scheduling flexibility post processing recovery and expansion behavior sensitivity to handling variables lot to…
For More InformationArmored CAR T
Strengthening T Cells for the Toughest Tumors CAR T therapy changed what is possible in blood cancers. But solid tumors remain one of the toughest frontiers in oncology. Not because we do not know what to target.Because the tumor environment fights back. Solid tumors suppress immune activity, block infiltration, and exhaust T cells before they…
For More InformationScaling Humanized Immune System Mouse Models: Optimize Your CD34+ Engraftment with High Quality Cells
Table of contents Key Takeaways CD34+ humanized mice enable better predictions for therapies, reducing the translational gap between humans and mice. High-quality CD34+ cells from CGT Global enhance engraftment success rates for HIS mice in preclinical studies. Cell viability, purity, and accurate counts are crucial for consistent and predictive data from these models. Ordering bulk…
For More Information